NCT03430895View on ClinicalTrials.gov

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
Non-Transitional Cell Carcinoma of the Urothelial TractSmall Cell of the BladderAdenocarcinoma of the BladderSquamous Cell Carcinoma of the BladderMetastatic Bladder Cancer
Interventions
DRUG

durvalumab and tremelimumab

Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memoral Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER